| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 160 | 2023 | 509 | 16.280 |
Why?
|
| Tomography, X-Ray Computed | 30 | 2021 | 698 | 4.640 |
Why?
|
| Mass Screening | 32 | 2023 | 168 | 4.390 |
Why?
|
| Early Detection of Cancer | 14 | 2023 | 90 | 3.450 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 40 | 2016 | 228 | 2.490 |
Why?
|
| Tomography, Spiral Computed | 15 | 2014 | 25 | 2.040 |
Why?
|
| Carcinoma, Small Cell | 42 | 2005 | 50 | 1.990 |
Why?
|
| Biomarkers, Tumor | 28 | 2010 | 184 | 1.800 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2021 | 45 | 1.710 |
Why?
|
| Humans | 188 | 2023 | 25692 | 1.530 |
Why?
|
| Antibodies, Monoclonal | 38 | 1999 | 185 | 1.440 |
Why?
|
| Smoking | 14 | 2015 | 165 | 1.170 |
Why?
|
| Emphysema | 2 | 2023 | 4 | 1.070 |
Why?
|
| Drug Design | 6 | 2013 | 23 | 1.050 |
Why?
|
| Multiple Pulmonary Nodules | 2 | 2014 | 12 | 0.940 |
Why?
|
| Peptides | 20 | 1997 | 104 | 0.870 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 2 | 0.850 |
Why?
|
| Neoplasms | 10 | 2014 | 224 | 0.850 |
Why?
|
| Tumor Cells, Cultured | 39 | 2005 | 110 | 0.850 |
Why?
|
| Anticarcinogenic Agents | 8 | 2005 | 16 | 0.790 |
Why?
|
| Neoplasm Proteins | 8 | 2007 | 45 | 0.780 |
Why?
|
| Drug Delivery Systems | 5 | 2009 | 29 | 0.750 |
Why?
|
| Breast Neoplasms | 11 | 2015 | 369 | 0.740 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2010 | 92 | 0.720 |
Why?
|
| Lung | 10 | 2023 | 159 | 0.700 |
Why?
|
| Growth Substances | 13 | 1996 | 29 | 0.700 |
Why?
|
| Sputum | 14 | 2005 | 20 | 0.680 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2003 | 29 | 0.660 |
Why?
|
| Occupational Exposure | 2 | 2018 | 16 | 0.630 |
Why?
|
| Systems Biology | 1 | 2018 | 5 | 0.620 |
Why?
|
| Antineoplastic Agents | 9 | 2016 | 169 | 0.620 |
Why?
|
| Radiation Exposure | 1 | 2018 | 9 | 0.620 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2018 | 11 | 0.620 |
Why?
|
| Tobacco Use Disorder | 1 | 2018 | 16 | 0.620 |
Why?
|
| Occupational Diseases | 1 | 2018 | 20 | 0.610 |
Why?
|
| Myocardial Ischemia | 1 | 2018 | 37 | 0.600 |
Why?
|
| Algorithms | 4 | 2015 | 347 | 0.590 |
Why?
|
| Lipoxygenase Inhibitors | 5 | 2001 | 6 | 0.580 |
Why?
|
| Radiographic Image Enhancement | 2 | 2015 | 27 | 0.570 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 8 | 2003 | 8 | 0.550 |
Why?
|
| United States | 15 | 2018 | 1943 | 0.540 |
Why?
|
| Thoracic Surgery, Video-Assisted | 2 | 2015 | 21 | 0.540 |
Why?
|
| Cell Division | 21 | 2003 | 79 | 0.520 |
Why?
|
| Sensitivity and Specificity | 13 | 2016 | 472 | 0.520 |
Why?
|
| DNA-Binding Proteins | 8 | 2003 | 249 | 0.510 |
Why?
|
| Genes, ras | 8 | 2003 | 13 | 0.510 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2014 | 217 | 0.510 |
Why?
|
| Gastrin-Releasing Peptide | 18 | 1999 | 18 | 0.500 |
Why?
|
| Actuarial Analysis | 3 | 2012 | 8 | 0.500 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2015 | 14 | 0.480 |
Why?
|
| Pneumonectomy | 2 | 2015 | 76 | 0.480 |
Why?
|
| Cyclooxygenase Inhibitors | 4 | 2004 | 27 | 0.470 |
Why?
|
| Publishing | 1 | 2014 | 38 | 0.460 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 163 | 0.450 |
Why?
|
| Growth Inhibitors | 6 | 1999 | 11 | 0.450 |
Why?
|
| Smoking Cessation | 5 | 2014 | 41 | 0.450 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2013 | 154 | 0.440 |
Why?
|
| Genome, Human | 1 | 2013 | 36 | 0.430 |
Why?
|
| Arachidonic Acid | 4 | 2001 | 14 | 0.430 |
Why?
|
| Female | 43 | 2018 | 14273 | 0.420 |
Why?
|
| Inflammation | 3 | 2009 | 261 | 0.410 |
Why?
|
| Diagnostic Imaging | 3 | 2010 | 66 | 0.410 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 1997 | 14 | 0.410 |
Why?
|
| Radiation Dosage | 8 | 2017 | 35 | 0.410 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2009 | 67 | 0.410 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 4 | 2003 | 23 | 0.400 |
Why?
|
| Insurance Benefits | 1 | 2012 | 1 | 0.400 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2007 | 52 | 0.400 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2004 | 19 | 0.400 |
Why?
|
| Neoplasm Staging | 14 | 2008 | 315 | 0.390 |
Why?
|
| Cost Savings | 1 | 2012 | 36 | 0.390 |
Why?
|
| Mesoderm | 2 | 2010 | 18 | 0.390 |
Why?
|
| Animals | 32 | 2010 | 3510 | 0.380 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 2 | 2009 | 2 | 0.380 |
Why?
|
| Male | 36 | 2018 | 13917 | 0.370 |
Why?
|
| Bombesin | 9 | 1997 | 9 | 0.370 |
Why?
|
| Transcription Factors | 2 | 2003 | 158 | 0.370 |
Why?
|
| Epithelium | 3 | 2010 | 26 | 0.370 |
Why?
|
| Reproducibility of Results | 8 | 2016 | 646 | 0.370 |
Why?
|
| Medical Oncology | 4 | 2014 | 35 | 0.360 |
Why?
|
| Precancerous Conditions | 5 | 2004 | 23 | 0.350 |
Why?
|
| Spirometry | 1 | 2010 | 11 | 0.350 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2010 | 16 | 0.350 |
Why?
|
| Proportional Hazards Models | 4 | 2010 | 332 | 0.340 |
Why?
|
| Hyaluronic Acid | 1 | 2010 | 51 | 0.340 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 52 | 0.340 |
Why?
|
| Gene Expression Profiling | 2 | 2007 | 128 | 0.330 |
Why?
|
| Chemokines | 1 | 2009 | 20 | 0.330 |
Why?
|
| Cost-Benefit Analysis | 5 | 2014 | 124 | 0.320 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 65 | 0.310 |
Why?
|
| Cytokines | 1 | 2010 | 212 | 0.310 |
Why?
|
| Arachidonate 5-Lipoxygenase | 2 | 1999 | 4 | 0.290 |
Why?
|
| Drug Approval | 1 | 2007 | 7 | 0.290 |
Why?
|
| Middle Aged | 27 | 2018 | 8403 | 0.290 |
Why?
|
| Immunohistochemistry | 11 | 2005 | 341 | 0.280 |
Why?
|
| Retinoids | 2 | 2005 | 5 | 0.280 |
Why?
|
| RNA, Messenger | 12 | 2003 | 284 | 0.280 |
Why?
|
| Isotretinoin | 4 | 2000 | 6 | 0.280 |
Why?
|
| Risk Assessment | 7 | 2014 | 618 | 0.280 |
Why?
|
| Indium Radioisotopes | 4 | 1999 | 5 | 0.280 |
Why?
|
| Ketorolac | 2 | 2004 | 12 | 0.270 |
Why?
|
| Chemoprevention | 2 | 2003 | 4 | 0.260 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 4 | 2017 | 29 | 0.260 |
Why?
|
| Mice | 19 | 2000 | 1345 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 4 | 2014 | 284 | 0.260 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2004 | 100 | 0.260 |
Why?
|
| Clinical Trials as Topic | 9 | 2006 | 209 | 0.250 |
Why?
|
| Head and Neck Neoplasms | 2 | 2005 | 146 | 0.240 |
Why?
|
| DNA Mutational Analysis | 2 | 2003 | 53 | 0.240 |
Why?
|
| Risk Factors | 11 | 2012 | 2224 | 0.240 |
Why?
|
| Epithelial Cells | 4 | 2005 | 72 | 0.240 |
Why?
|
| Leukoplakia, Oral | 1 | 2004 | 2 | 0.230 |
Why?
|
| Signal Transduction | 5 | 2001 | 410 | 0.230 |
Why?
|
| Antigens, Neoplasm | 9 | 1994 | 37 | 0.230 |
Why?
|
| Transferrin | 3 | 1996 | 6 | 0.220 |
Why?
|
| Mass Chest X-Ray | 1 | 2003 | 1 | 0.220 |
Why?
|
| Insulin-Like Growth Factor I | 8 | 2001 | 52 | 0.220 |
Why?
|
| Carrier Proteins | 3 | 1999 | 96 | 0.220 |
Why?
|
| Prognosis | 10 | 2005 | 739 | 0.210 |
Why?
|
| Cell Hypoxia | 1 | 2003 | 11 | 0.210 |
Why?
|
| Isoenzymes | 3 | 2000 | 51 | 0.210 |
Why?
|
| Apoptosis | 2 | 2001 | 177 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 20 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 4 | 2010 | 75 | 0.210 |
Why?
|
| Down-Regulation | 1 | 2003 | 94 | 0.200 |
Why?
|
| Survival Rate | 6 | 2016 | 308 | 0.200 |
Why?
|
| Thoracic Surgical Procedures | 2 | 2012 | 9 | 0.200 |
Why?
|
| Biomarkers | 6 | 2015 | 554 | 0.190 |
Why?
|
| Quality Assurance, Health Care | 2 | 2017 | 33 | 0.190 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2001 | 1 | 0.190 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 21 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 3 | 1997 | 37 | 0.190 |
Why?
|
| Smoking Prevention | 3 | 2013 | 16 | 0.180 |
Why?
|
| Adenocarcinoma | 6 | 1998 | 132 | 0.180 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2000 | 2 | 0.180 |
Why?
|
| Disease Management | 1 | 2001 | 97 | 0.180 |
Why?
|
| Membrane Proteins | 2 | 1999 | 151 | 0.180 |
Why?
|
| Software | 2 | 2014 | 63 | 0.180 |
Why?
|
| Carcinoma | 2 | 1999 | 63 | 0.180 |
Why?
|
| Databases, Factual | 2 | 2006 | 329 | 0.170 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 1996 | 20 | 0.170 |
Why?
|
| Interleukin-6 | 1 | 2000 | 74 | 0.170 |
Why?
|
| Aged | 19 | 2018 | 8501 | 0.170 |
Why?
|
| Radioimmunodetection | 1 | 1999 | 1 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 8 | 2003 | 111 | 0.170 |
Why?
|
| Multienzyme Complexes | 3 | 1999 | 27 | 0.170 |
Why?
|
| Advisory Committees | 3 | 2014 | 19 | 0.160 |
Why?
|
| Molecular Sequence Data | 14 | 1996 | 169 | 0.160 |
Why?
|
| Nuclear Weapons | 1 | 2018 | 1 | 0.160 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1998 | 34 | 0.160 |
Why?
|
| Genetic Markers | 2 | 2000 | 36 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 2 | 1993 | 89 | 0.150 |
Why?
|
| Receptors, Transferrin | 2 | 1996 | 4 | 0.150 |
Why?
|
| Retinoblastoma Protein | 2 | 1995 | 10 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2005 | 311 | 0.150 |
Why?
|
| Thoracic Neoplasms | 2 | 2017 | 8 | 0.150 |
Why?
|
| Microscopy | 1 | 1997 | 10 | 0.140 |
Why?
|
| Lymphoma | 4 | 1991 | 30 | 0.140 |
Why?
|
| Adult | 15 | 2018 | 7336 | 0.140 |
Why?
|
| Point Mutation | 1 | 1997 | 25 | 0.140 |
Why?
|
| Gallium | 1 | 1996 | 2 | 0.130 |
Why?
|
| Biological Specimen Banks | 1 | 1996 | 8 | 0.130 |
Why?
|
| Military Medicine | 1 | 1996 | 8 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 6 | 2000 | 98 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 5 | 1993 | 36 | 0.120 |
Why?
|
| Indoles | 3 | 2001 | 35 | 0.120 |
Why?
|
| Vascular Calcification | 1 | 2015 | 9 | 0.120 |
Why?
|
| Radioimmunoassay | 5 | 1993 | 16 | 0.120 |
Why?
|
| Coronary Vessels | 1 | 2015 | 33 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2006 | 222 | 0.120 |
Why?
|
| Base Sequence | 7 | 2003 | 90 | 0.120 |
Why?
|
| Blotting, Northern | 5 | 2003 | 20 | 0.120 |
Why?
|
| Health Policy | 1 | 2015 | 42 | 0.120 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2005 | 12 | 0.120 |
Why?
|
| Skin Neoplasms | 3 | 1991 | 66 | 0.120 |
Why?
|
| Mutation | 5 | 2016 | 325 | 0.120 |
Why?
|
| Mice, Nude | 8 | 1998 | 22 | 0.120 |
Why?
|
| Mesothelioma | 1 | 1994 | 13 | 0.120 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 7 | 0.120 |
Why?
|
| Physician's Role | 1 | 2014 | 17 | 0.120 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2014 | 2 | 0.110 |
Why?
|
| Nuclear Proteins | 3 | 2003 | 80 | 0.110 |
Why?
|
| International Agencies | 1 | 2014 | 3 | 0.110 |
Why?
|
| Amino Acid Sequence | 10 | 1996 | 137 | 0.110 |
Why?
|
| Lymph Nodes | 4 | 1991 | 66 | 0.110 |
Why?
|
| Tobacco Use Cessation | 1 | 2013 | 1 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2013 | 30 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2004 | 91 | 0.110 |
Why?
|
| DNA Primers | 4 | 2003 | 46 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 170 | 0.110 |
Why?
|
| Incidence | 3 | 2010 | 731 | 0.110 |
Why?
|
| ErbB Receptors | 2 | 2010 | 52 | 0.110 |
Why?
|
| Radiography, Thoracic | 2 | 2005 | 25 | 0.100 |
Why?
|
| Neuropeptides | 2 | 1995 | 24 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2000 | 8 | 0.100 |
Why?
|
| Eicosanoids | 2 | 2003 | 2 | 0.100 |
Why?
|
| Codon | 4 | 2003 | 5 | 0.100 |
Why?
|
| Patient Education as Topic | 2 | 2005 | 140 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 1999 | 10 | 0.100 |
Why?
|
| Oncogenes | 5 | 1993 | 9 | 0.100 |
Why?
|
| Protein Binding | 2 | 2009 | 116 | 0.100 |
Why?
|
| Research | 1 | 1992 | 38 | 0.100 |
Why?
|
| Receptors, Retinoic Acid | 3 | 2000 | 3 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 6 | 1998 | 29 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2000 | 325 | 0.090 |
Why?
|
| Microsatellite Repeats | 2 | 2001 | 9 | 0.090 |
Why?
|
| Combined Modality Therapy | 7 | 2016 | 281 | 0.090 |
Why?
|
| Aerosols | 2 | 2002 | 22 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 1990 | 1 | 0.090 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2010 | 3 | 0.090 |
Why?
|
| Spain | 1 | 2010 | 7 | 0.090 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 7 | 0.090 |
Why?
|
| Glucuronosyltransferase | 1 | 2010 | 4 | 0.090 |
Why?
|
| Hyaluronan Synthases | 1 | 2010 | 5 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2010 | 20 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 51 | 0.090 |
Why?
|
| Age Distribution | 1 | 2010 | 84 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2010 | 75 | 0.090 |
Why?
|
| Data Collection | 1 | 1990 | 93 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 45 | 0.090 |
Why?
|
| RNA, Neoplasm | 5 | 1999 | 10 | 0.090 |
Why?
|
| Hyperplasia | 2 | 2000 | 17 | 0.080 |
Why?
|
| Mice, Inbred A | 2 | 2000 | 2 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 221 | 0.080 |
Why?
|
| Quality of Life | 1 | 2014 | 600 | 0.080 |
Why?
|
| Disease Progression | 4 | 2008 | 664 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2006 | 198 | 0.080 |
Why?
|
| Phenotype | 1 | 2010 | 292 | 0.080 |
Why?
|
| Tissue Distribution | 9 | 1998 | 32 | 0.080 |
Why?
|
| Prospective Studies | 6 | 2008 | 1633 | 0.080 |
Why?
|
| DNA, Neoplasm | 4 | 1998 | 18 | 0.080 |
Why?
|
| Prevalence | 1 | 2010 | 435 | 0.080 |
Why?
|
| Gastrins | 3 | 1993 | 4 | 0.080 |
Why?
|
| Time Factors | 5 | 2000 | 1336 | 0.080 |
Why?
|
| Immunoglobulin G | 3 | 1999 | 92 | 0.080 |
Why?
|
| Gene Deletion | 2 | 2000 | 36 | 0.080 |
Why?
|
| Liver Neoplasms | 3 | 1990 | 93 | 0.080 |
Why?
|
| Radionuclide Imaging | 7 | 1991 | 38 | 0.070 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 2 | 1999 | 2 | 0.070 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2007 | 4 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2007 | 8 | 0.070 |
Why?
|
| Patient Selection | 2 | 2014 | 170 | 0.070 |
Why?
|
| Mixed Function Oxygenases | 3 | 1999 | 4 | 0.070 |
Why?
|
| Radiology Information Systems | 1 | 2007 | 2 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2007 | 22 | 0.070 |
Why?
|
| Regression Analysis | 1 | 1988 | 255 | 0.070 |
Why?
|
| Medical Laboratory Science | 1 | 2007 | 7 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 1999 | 97 | 0.070 |
Why?
|
| Models, Biological | 3 | 2004 | 311 | 0.070 |
Why?
|
| Masoprocol | 2 | 1998 | 6 | 0.070 |
Why?
|
| Carcinogens | 2 | 2000 | 10 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 574 | 0.070 |
Why?
|
| Genes, p53 | 2 | 2000 | 16 | 0.070 |
Why?
|
| Age Factors | 4 | 2012 | 716 | 0.070 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2006 | 2 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2006 | 341 | 0.070 |
Why?
|
| Europe | 1 | 2006 | 64 | 0.070 |
Why?
|
| Iodine Radioisotopes | 3 | 1993 | 13 | 0.060 |
Why?
|
| Culture Media, Conditioned | 3 | 2000 | 17 | 0.060 |
Why?
|
| Cell Line | 12 | 1992 | 268 | 0.060 |
Why?
|
| Bronchoalveolar Lavage | 2 | 2003 | 2 | 0.060 |
Why?
|
| Ligases | 2 | 2003 | 10 | 0.060 |
Why?
|
| HeLa Cells | 2 | 2003 | 39 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2005 | 45 | 0.060 |
Why?
|
| Apudoma | 1 | 1984 | 1 | 0.060 |
Why?
|
| Angiomatosis | 1 | 1984 | 3 | 0.060 |
Why?
|
| Pheochromocytoma | 1 | 1984 | 7 | 0.060 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1984 | 6 | 0.060 |
Why?
|
| Liver | 3 | 2000 | 144 | 0.060 |
Why?
|
| Spectrum Analysis | 1 | 2004 | 8 | 0.060 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 12 | 0.060 |
Why?
|
| Mouth Neoplasms | 1 | 2004 | 20 | 0.060 |
Why?
|
| Mouthwashes | 1 | 2004 | 6 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2005 | 167 | 0.060 |
Why?
|
| Placebos | 1 | 2004 | 68 | 0.060 |
Why?
|
| Proteins | 2 | 1996 | 52 | 0.060 |
Why?
|
| Protein Precursors | 5 | 1996 | 15 | 0.060 |
Why?
|
| Cytodiagnosis | 2 | 1993 | 17 | 0.060 |
Why?
|
| Rats | 5 | 2000 | 649 | 0.060 |
Why?
|
| Administration, Inhalation | 2 | 2000 | 34 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2003 | 21 | 0.050 |
Why?
|
| Dinoprostone | 2 | 2000 | 16 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2003 | 32 | 0.050 |
Why?
|
| Immunotherapy | 3 | 2016 | 53 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2003 | 1 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 31 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2003 | 96 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2003 | 10 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2004 | 396 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2003 | 93 | 0.050 |
Why?
|
| Indium | 3 | 1987 | 7 | 0.050 |
Why?
|
| Enzyme Induction | 2 | 2000 | 18 | 0.050 |
Why?
|
| Somatomedins | 2 | 1996 | 4 | 0.050 |
Why?
|
| Radioisotopes | 3 | 1987 | 12 | 0.050 |
Why?
|
| Amides | 3 | 1998 | 16 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2003 | 75 | 0.050 |
Why?
|
| International Cooperation | 1 | 2002 | 22 | 0.050 |
Why?
|
| Culture Media | 2 | 1996 | 29 | 0.050 |
Why?
|
| Neoplasm Transplantation | 3 | 1998 | 12 | 0.050 |
Why?
|
| Etoposide | 5 | 1996 | 25 | 0.050 |
Why?
|
| Canada | 2 | 2012 | 48 | 0.050 |
Why?
|
| Cisplatin | 5 | 1996 | 49 | 0.050 |
Why?
|
| Survival Analysis | 5 | 2010 | 246 | 0.050 |
Why?
|
| Proteomics | 1 | 2002 | 85 | 0.050 |
Why?
|
| Population Surveillance | 2 | 2012 | 103 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2001 | 13 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2013 | 138 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2001 | 18 | 0.050 |
Why?
|
| Pulmonary Surfactants | 2 | 1992 | 4 | 0.050 |
Why?
|
| Proteolipids | 2 | 1992 | 5 | 0.050 |
Why?
|
| Respiratory System | 2 | 1992 | 7 | 0.050 |
Why?
|
| Ligands | 1 | 2001 | 37 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2000 | 322 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 4 | 1999 | 4 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 31 | 0.050 |
Why?
|
| Public Health | 1 | 2001 | 66 | 0.050 |
Why?
|
| Biopsy | 3 | 2012 | 199 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 1997 | 443 | 0.050 |
Why?
|
| Ribonucleoproteins | 1 | 2000 | 3 | 0.050 |
Why?
|
| Binding Sites | 2 | 1993 | 65 | 0.050 |
Why?
|
| Immunologic Tests | 1 | 2000 | 3 | 0.050 |
Why?
|
| Drug Evaluation | 3 | 1990 | 19 | 0.050 |
Why?
|
| Methylation | 1 | 2000 | 7 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2000 | 5 | 0.050 |
Why?
|
| Comorbidity | 2 | 2012 | 457 | 0.040 |
Why?
|
| HL-60 Cells | 1 | 2000 | 8 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2000 | 3 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2000 | 4 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2000 | 17 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2000 | 35 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2000 | 17 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2000 | 23 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 16 | 0.040 |
Why?
|
| Particle Size | 1 | 2000 | 48 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2000 | 15 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2000 | 48 | 0.040 |
Why?
|
| Antibodies | 1 | 2000 | 48 | 0.040 |
Why?
|
| Receptors, Neurotransmitter | 2 | 1991 | 5 | 0.040 |
Why?
|
| RNA, Heterogeneous Nuclear | 1 | 1999 | 1 | 0.040 |
Why?
|
| Fetus | 2 | 1998 | 37 | 0.040 |
Why?
|
| Dogs | 2 | 1991 | 176 | 0.040 |
Why?
|
| Cyclooxygenase 1 | 1 | 1999 | 6 | 0.040 |
Why?
|
| Injections, Subcutaneous | 2 | 1991 | 24 | 0.040 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 1999 | 3 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 1999 | 26 | 0.040 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 1999 | 19 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 1999 | 2 | 0.040 |
Why?
|
| Cinnamates | 1 | 1999 | 8 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2000 | 392 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2000 | 262 | 0.040 |
Why?
|
| CD5 Antigens | 1 | 1998 | 1 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 1998 | 6 | 0.040 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 1998 | 5 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1998 | 14 | 0.040 |
Why?
|
| Yttrium Radioisotopes | 1 | 1998 | 10 | 0.040 |
Why?
|
| Capillaries | 1 | 1998 | 11 | 0.040 |
Why?
|
| Mammals | 1 | 1998 | 18 | 0.040 |
Why?
|
| Pregnancy | 2 | 1998 | 291 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 1999 | 56 | 0.040 |
Why?
|
| Pyridines | 1 | 1998 | 36 | 0.040 |
Why?
|
| Lipoxygenase | 1 | 1998 | 1 | 0.040 |
Why?
|
| Benzoquinones | 1 | 1998 | 2 | 0.040 |
Why?
|
| Quinolines | 1 | 1998 | 7 | 0.040 |
Why?
|
| Bronchi | 1 | 1998 | 12 | 0.040 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 1996 | 5 | 0.040 |
Why?
|
| Lung Diseases | 1 | 1998 | 42 | 0.040 |
Why?
|
| Stimulation, Chemical | 2 | 2000 | 8 | 0.040 |
Why?
|
| Cell Differentiation | 4 | 1992 | 127 | 0.040 |
Why?
|
| Antigens, Surface | 4 | 1986 | 12 | 0.040 |
Why?
|
| Remission Induction | 3 | 1996 | 80 | 0.040 |
Why?
|
| beta Carotene | 1 | 1997 | 13 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 37 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2017 | 18 | 0.040 |
Why?
|
| Nurse-Patient Relations | 1 | 2017 | 57 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2006 | 1689 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2008 | 84 | 0.030 |
Why?
|
| Liver Function Tests | 2 | 1988 | 19 | 0.030 |
Why?
|
| Drug Resistance | 3 | 1994 | 37 | 0.030 |
Why?
|
| In Vitro Techniques | 3 | 1992 | 157 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 1996 | 9 | 0.030 |
Why?
|
| Diet | 2 | 2000 | 207 | 0.030 |
Why?
|
| Communication | 1 | 2017 | 119 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 1996 | 71 | 0.030 |
Why?
|
| Aminopterin | 1 | 1996 | 1 | 0.030 |
Why?
|
| Folic Acid Antagonists | 1 | 1996 | 1 | 0.030 |
Why?
|
| Dipyridamole | 1 | 1996 | 2 | 0.030 |
Why?
|
| Computer Communication Networks | 1 | 1996 | 3 | 0.030 |
Why?
|
| Maryland | 1 | 1996 | 7 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 1996 | 19 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 203 | 0.030 |
Why?
|
| Molecular Biology | 2 | 2007 | 11 | 0.030 |
Why?
|
| Gene Expression | 1 | 1996 | 182 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 1996 | 57 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2008 | 119 | 0.030 |
Why?
|
| Antigens, Differentiation | 1 | 1994 | 9 | 0.030 |
Why?
|
| Cell Membrane | 2 | 1993 | 85 | 0.030 |
Why?
|
| Receptors, Estrogen | 2 | 2005 | 56 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1994 | 75 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2008 | 36 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1993 | 2 | 0.030 |
Why?
|
| Arginine Vasopressin | 1 | 1993 | 2 | 0.030 |
Why?
|
| Inositol | 1 | 1993 | 6 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 1993 | 17 | 0.030 |
Why?
|
| Mitogens | 1 | 1992 | 5 | 0.030 |
Why?
|
| Sodium | 1 | 1993 | 61 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 913 | 0.030 |
Why?
|
| Uteroglobin | 1 | 1992 | 1 | 0.020 |
Why?
|
| Amidine-Lyases | 1 | 1991 | 1 | 0.020 |
Why?
|
| Chromogranins | 2 | 1988 | 3 | 0.020 |
Why?
|
| Hormones | 1 | 1991 | 9 | 0.020 |
Why?
|
| Gastric Acid | 1 | 1991 | 7 | 0.020 |
Why?
|
| Tamoxifen | 1 | 1992 | 26 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2006 | 3231 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1991 | 1 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 1992 | 3220 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1991 | 9 | 0.020 |
Why?
|
| Tretinoin | 1 | 1991 | 13 | 0.020 |
Why?
|
| Chromosome Disorders | 1 | 1991 | 10 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 1991 | 39 | 0.020 |
Why?
|
| Palliative Care | 2 | 1996 | 99 | 0.020 |
Why?
|
| Adenoma | 1 | 1992 | 56 | 0.020 |
Why?
|
| Injections | 1 | 1991 | 43 | 0.020 |
Why?
|
| Blotting, Western | 3 | 1996 | 140 | 0.020 |
Why?
|
| Carboplatin | 1 | 1990 | 20 | 0.020 |
Why?
|
| Insulin | 2 | 1988 | 83 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2001 | 150 | 0.020 |
Why?
|
| Chromosome Deletion | 2 | 1990 | 14 | 0.020 |
Why?
|
| Glycosphingolipids | 1 | 1989 | 1 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 25 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 85 | 0.020 |
Why?
|
| SEER Program | 1 | 2010 | 37 | 0.020 |
Why?
|
| Glycolipids | 2 | 1986 | 2 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 120 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 1989 | 27 | 0.020 |
Why?
|
| Mating Factor | 1 | 1989 | 1 | 0.020 |
Why?
|
| Chemistry | 1 | 1989 | 2 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1989 | 4 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1989 | 17 | 0.020 |
Why?
|
| Registries | 1 | 2010 | 170 | 0.020 |
Why?
|
| Glutaral | 1 | 1988 | 1 | 0.020 |
Why?
|
| Polyvinyl Chloride | 1 | 1988 | 1 | 0.020 |
Why?
|
| Fixatives | 1 | 1988 | 5 | 0.020 |
Why?
|
| Aromatic-L-Amino-Acid Decarboxylases | 1 | 1988 | 1 | 0.020 |
Why?
|
| Dopa Decarboxylase | 1 | 1988 | 1 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 1988 | 3 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 1988 | 9 | 0.020 |
Why?
|
| Random Allocation | 1 | 1988 | 116 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 1988 | 2 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 1988 | 4 | 0.020 |
Why?
|
| Selenium | 1 | 1988 | 9 | 0.020 |
Why?
|
| Thiazoles | 1 | 1988 | 19 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 1988 | 76 | 0.020 |
Why?
|
| Antibody Formation | 1 | 1988 | 16 | 0.020 |
Why?
|
| Estradiol | 1 | 1988 | 33 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 1988 | 35 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 48 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 126 | 0.020 |
Why?
|
| Contrast Media | 1 | 2008 | 68 | 0.020 |
Why?
|
| Databases, Protein | 1 | 2007 | 1 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 14 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1987 | 6 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 1988 | 140 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 1987 | 24 | 0.020 |
Why?
|
| Spleen | 1 | 1987 | 32 | 0.020 |
Why?
|
| Research Design | 1 | 1988 | 188 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1996 | 13 | 0.020 |
Why?
|
| Vincristine | 2 | 1996 | 17 | 0.020 |
Why?
|
| Gene Amplification | 1 | 1986 | 18 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 1996 | 43 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1996 | 26 | 0.020 |
Why?
|
| Doxorubicin | 2 | 1996 | 47 | 0.020 |
Why?
|
| Methotrexate | 2 | 1996 | 34 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 1985 | 1 | 0.020 |
Why?
|
| Avidin | 1 | 1985 | 1 | 0.020 |
Why?
|
| Ovalbumin | 1 | 1985 | 6 | 0.020 |
Why?
|
| Biotin | 1 | 1985 | 7 | 0.020 |
Why?
|
| HLA Antigens | 1 | 1985 | 16 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 15 | 0.020 |
Why?
|
| Pedigree | 1 | 1984 | 48 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2005 | 28 | 0.010 |
Why?
|
| Lewis X Antigen | 1 | 1984 | 1 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1984 | 10 | 0.010 |
Why?
|
| Receptors, Bombesin | 3 | 1991 | 3 | 0.010 |
Why?
|
| Oligosaccharides | 1 | 1984 | 15 | 0.010 |
Why?
|
| Sulfur | 1 | 1984 | 2 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1984 | 5 | 0.010 |
Why?
|
| Technetium | 1 | 1984 | 4 | 0.010 |
Why?
|
| Cell Survival | 2 | 1998 | 110 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 2004 | 36 | 0.010 |
Why?
|
| Microscopy, Electron | 2 | 1998 | 61 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2004 | 52 | 0.010 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1984 | 4 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1983 | 2 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1983 | 5 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2004 | 183 | 0.010 |
Why?
|
| Immunoblotting | 2 | 1996 | 50 | 0.010 |
Why?
|
| Drug Synergism | 2 | 1996 | 40 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 1996 | 76 | 0.010 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2002 | 6 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2002 | 61 | 0.010 |
Why?
|
| Epitopes | 2 | 1996 | 44 | 0.010 |
Why?
|
| Rabbits | 2 | 1996 | 184 | 0.010 |
Why?
|
| Transcription, Genetic | 2 | 1996 | 100 | 0.010 |
Why?
|
| Pulmonary Surfactant-Associated Proteins | 2 | 1992 | 2 | 0.010 |
Why?
|
| Mice, Inbred SENCAR | 1 | 2000 | 1 | 0.010 |
Why?
|
| Transglutaminases | 1 | 2000 | 2 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2000 | 10 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 1991 | 256 | 0.010 |
Why?
|
| Receptors, Cell Surface | 2 | 1992 | 37 | 0.010 |
Why?
|
| Ditiocarb | 1 | 1999 | 1 | 0.010 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 1999 | 2 | 0.010 |
Why?
|
| Hygromycin B | 1 | 1999 | 2 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1999 | 11 | 0.010 |
Why?
|
| Histocytochemistry | 2 | 1992 | 16 | 0.010 |
Why?
|
| Radioimmunotherapy | 1 | 1998 | 1 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 112 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1998 | 7 | 0.010 |
Why?
|
| Cell Death | 1 | 1998 | 40 | 0.010 |
Why?
|
| Chromogranin A | 2 | 1988 | 10 | 0.010 |
Why?
|
| Carbohydrate Sequence | 2 | 1989 | 5 | 0.010 |
Why?
|
| Transplantation, Heterologous | 2 | 1990 | 17 | 0.010 |
Why?
|
| Proto-Oncogenes | 2 | 1990 | 2 | 0.010 |
Why?
|
| Tin | 1 | 1997 | 1 | 0.010 |
Why?
|
| Mining | 1 | 1997 | 3 | 0.010 |
Why?
|
| China | 1 | 1997 | 46 | 0.010 |
Why?
|
| Calcium | 2 | 1991 | 364 | 0.010 |
Why?
|
| Deoxyglucose | 1 | 1996 | 2 | 0.010 |
Why?
|
| Fluorine Radioisotopes | 1 | 1996 | 5 | 0.010 |
Why?
|
| Breast | 1 | 1996 | 22 | 0.010 |
Why?
|
| Cyanogen Bromide | 1 | 1996 | 1 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1996 | 5 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1996 | 4 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1987 | 88 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 1996 | 37 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 333 | 0.010 |
Why?
|
| Mammography | 1 | 1996 | 41 | 0.010 |
Why?
|
| Cranial Irradiation | 1 | 1996 | 13 | 0.010 |
Why?
|
| Lomustine | 1 | 1996 | 1 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 1996 | 1 | 0.010 |
Why?
|
| Nucleosides | 1 | 1996 | 2 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1996 | 3 | 0.010 |
Why?
|
| Carmustine | 1 | 1996 | 2 | 0.010 |
Why?
|
| Thymidine | 1 | 1996 | 6 | 0.010 |
Why?
|
| Immune Sera | 1 | 1996 | 5 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1996 | 5 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1996 | 18 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1996 | 10 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 1996 | 22 | 0.010 |
Why?
|
| Biological Transport | 1 | 1996 | 38 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1996 | 32 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 36 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1996 | 69 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1996 | 110 | 0.010 |
Why?
|
| Cause of Death | 1 | 1996 | 63 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1996 | 43 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1995 | 3 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 1995 | 6 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1995 | 8 | 0.010 |
Why?
|
| Homozygote | 1 | 1995 | 17 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1995 | 17 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1996 | 72 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1995 | 19 | 0.010 |
Why?
|
| Triglycerides | 1 | 1995 | 57 | 0.010 |
Why?
|
| Drug Therapy | 1 | 1995 | 9 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 2 | 1985 | 5 | 0.010 |
Why?
|
| Leukopenia | 1 | 1994 | 5 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1994 | 20 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1994 | 8 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 152 | 0.010 |
Why?
|
| Adolescent | 2 | 1994 | 2076 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 1994 | 6 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 1994 | 6 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1994 | 81 | 0.010 |
Why?
|
| Weight Loss | 1 | 1994 | 105 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1993 | 7 | 0.010 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 1993 | 2 | 0.010 |
Why?
|
| Hyponatremia | 1 | 1993 | 8 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2001 | 4459 | 0.010 |
Why?
|
| Infant | 1 | 1994 | 529 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1992 | 69 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1992 | 16 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1994 | 640 | 0.010 |
Why?
|
| Lyases | 1 | 1991 | 7 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1994 | 588 | 0.010 |
Why?
|
| Exons | 1 | 1992 | 29 | 0.010 |
Why?
|
| Glycine | 1 | 1991 | 12 | 0.010 |
Why?
|
| Genetic Testing | 1 | 1992 | 56 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1991 | 4 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1991 | 1 | 0.010 |
Why?
|
| Karyotyping | 1 | 1991 | 8 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1991 | 26 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1991 | 11 | 0.010 |
Why?
|
| Alleles | 1 | 1991 | 190 | 0.010 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 1990 | 1 | 0.010 |
Why?
|
| DNA Probes | 1 | 1990 | 7 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1990 | 34 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1990 | 43 | 0.010 |
Why?
|
| Hormones, Ectopic | 1 | 1990 | 1 | 0.010 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1990 | 1 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1990 | 13 | 0.010 |
Why?
|
| Carbohydrate Conformation | 1 | 1989 | 5 | 0.010 |
Why?
|
| Body Fluids | 1 | 1990 | 13 | 0.010 |
Why?
|
| Child | 1 | 1994 | 1277 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1988 | 4 | 0.000 |
Why?
|
| Leucine | 1 | 1988 | 10 | 0.000 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1988 | 12 | 0.000 |
Why?
|
| Peptide Biosynthesis | 1 | 1988 | 1 | 0.000 |
Why?
|
| Carcinoid Tumor | 1 | 1988 | 5 | 0.000 |
Why?
|
| Type C Phospholipases | 1 | 1988 | 8 | 0.000 |
Why?
|
| Cell Communication | 1 | 1988 | 20 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1988 | 30 | 0.000 |
Why?
|
| Receptor, Insulin | 1 | 1988 | 1 | 0.000 |
Why?
|
| Receptors, Somatomedin | 1 | 1988 | 4 | 0.000 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1987 | 3 | 0.000 |
Why?
|
| Immunization | 1 | 1987 | 15 | 0.000 |
Why?
|
| Immunoglobulin M | 1 | 1987 | 14 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1987 | 55 | 0.000 |
Why?
|
| Whole-Body Counting | 1 | 1987 | 2 | 0.000 |
Why?
|
| Lymphatic System | 1 | 1987 | 4 | 0.000 |
Why?
|
| Drug Carriers | 1 | 1987 | 7 | 0.000 |
Why?
|
| Mycosis Fungoides | 1 | 1987 | 5 | 0.000 |
Why?
|
| P Blood-Group System | 1 | 1986 | 1 | 0.000 |
Why?
|
| Gangliosides | 1 | 1986 | 6 | 0.000 |
Why?
|
| ABO Blood-Group System | 1 | 1986 | 5 | 0.000 |
Why?
|
| Kinetics | 1 | 1987 | 179 | 0.000 |
Why?
|
| Melanoma | 1 | 1987 | 52 | 0.000 |
Why?
|
| Cell Separation | 1 | 1986 | 28 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1986 | 32 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1992 | 827 | 0.000 |
Why?
|
| Cytogenetics | 1 | 1986 | 1 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1986 | 107 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1985 | 21 | 0.000 |
Why?
|
| Genes, MHC Class II | 1 | 1985 | 1 | 0.000 |
Why?
|
| Interferons | 1 | 1985 | 7 | 0.000 |
Why?
|
| HLA-B Antigens | 1 | 1985 | 8 | 0.000 |
Why?
|
| HLA-A Antigens | 1 | 1985 | 13 | 0.000 |
Why?
|
| HLA-C Antigens | 1 | 1985 | 10 | 0.000 |
Why?
|
| Peroxidase | 1 | 1985 | 15 | 0.000 |
Why?
|
| Peroxidases | 1 | 1985 | 7 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 23 | 0.000 |
Why?
|
| Aging | 1 | 1992 | 1429 | 0.000 |
Why?
|